Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bone Metastases
(18)FDG-PET should complement bone scintigraphy for detecting bone metastases
February 14th, 2006
(18)FDG-PET should be used as a complement to bone scintigraphy in detecting bone metastases in patients with breast cancer. According to a study from Japan, "Bone is one of the most common sites of metastasis in breast cancer patients. Although bone scintigraphy is widely used to detect metastatic breast cancer, the usefulness of (18)FDG-PET for detecting bone metastasis has not been clearly evaluated." "The purpose of this study was to compare the diagnostic accuracy of (18)FDG-PET with bone scintigraphy in detecting bone metastasis in breast cancer patients. Forty-four women aged 35 to 81 years (mean, 56 years) with breast cancer were examined in...
Source: Cancer Weekly (2006-02-14)
|
